Serial Number
85076127
Owner
NANT HOLDINGS IP, LLCAttorney
Michael J. McCueFirst Use Date
Mar 5, 2015
Filing Date
Jul 1, 2010
GLOBAL HEALTH GRID Trademark
Serial Number: 85076127 • Registration: 4735454
Trademark Classes
Owner Contact Info
11755 WILSHIRE BOULEVARD
LOS ANGELES, CA 90025
Entity Type: 16
149 S. Barrington Avenue #649
Los Angeles, CA 90049
Entity Type: 16
Legal Representation
Trademark Details
Filing Date
July 1, 2010
Registration Date
May 12, 2015
First Use Anywhere
March 5, 2015
First Use in Commerce
March 5, 2015
Published for Opposition
January 17, 2012
Cancellation Date
November 19, 2021
Goods & Services
Telecommunication services, namely, providing electronic transmission of data and documents over computerized electronic communications networks
Health care cost review and cost containment services; data collection processing and data services, namely, data collection, data processing and data management for business purposes in the fields of medicine and healthcare; providing technical consulting services and information management services, namely, clinical data and regulatory submission management to medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; services comprising the recording, transcription, composition, compilation and systematization of health and medical data
Information technology and data services, namely, integration of computer systems and networks; computer services, namely, creating searchable databases of information and data and for the collection, editing, organizing, modifying, book marking, transmission, storage and sharing of health and medical data and generation of reports thereof; data collection, data processing and data management in the fields of medicine and healthcare to evaluate, analyze and collect service data and data services, namely, electronic data collection and data submission services for developing, testing and validating next-generation diagnostics and pharmaceuticals to target pre-select patients based on molecular profiles to predict drug response to particular therapeutics